High Stereo-Selectivity Icon
Enzymatic synthesis guarantees the exclusive production of the desired alpha-Arbutin isomer, avoiding racemic mixtures .
Arbutin (hydroquinone beta-D-glucopyranoside) is a highly valued molecule in cosmetics and skincare for its melanin-inhibiting (whitening) properties. Industrial sourcing faces major hurdles. Traditional extraction from bearberry (Arctostaphylos uva-ursi) is low-yielding and environmentally unsustainable due to reliance on wild harvest. Furthermore, chemical synthesis often produces racemic mixtures , yielding both alpha-Arbutin and beta-Arbutin, where alpha-Arbutin is often desired for stability and superior activity. The key to high-quality production is the specific alpha-glycosylation step.
CD Biosynsis offers a cutting-edge enzymatic and microbial engineering solution. The first approach is Enzymatic synthesis (bioconversion) using alpha-glucosidase and hydroquinone}/\text{glucose as substrates . This method is favored for its high stereo-selectivity, ensuring the production of the desired alpha-Arbutin isomer. The second, more comprehensive approach, is Engineering microbial hosts to enhance the production of hydroquinone (precursor) and the final glycosylation step . This involves metabolic engineering to increase hydroquinone production from glucose (via the Shikimate pathway) and then coupling it with an engineered Glycosyltransferase enzyme (UGT) or highly active alpha-Glucosidase for a single-step, high-yield biological production process. This bio-route delivers a sustainable, cost-effective, and high-purity supply of alpha-Arbutin.
Get a QuoteIndustrial Arbutin production faces these key challenges:
A successful solution must ensure highly selective production of the alpha-Arbutin isomer at a high titer, independent of plant material.
CD Biosynsis utilizes advanced metabolic and enzymatic engineering to optimize Arbutin production:
Enzymatic Bioconversion with Engineered alpha-Glucosidase
We engineer alpha-Glucosidase for high trans-glycosylation efficiency to convert hydroquinone and glucose directly to pure alpha-Arbutin in vitro.
Enhance Hydroquinone Precursor Production in Hosts
We metabolically engineer E. coli or yeast by boosting the Shikimate pathway and introducing key degradation enzymes to maximize hydroquinone titer from glucose.
Optimize the Final Glycosylation Step (UGT)
For whole-cell synthesis, we introduce and optimize a highly selective UGT (Uridine-diphospho-glycosyltransferase) to perform the final alpha-glycosylation step.
Increase Product Tolerance and Recovery
We address substrate (hydroquinone) and product (Arbutin) toxicity by engineering membrane transport or in situ adsorption to boost final titer .
This systematic approach yields high-purity alpha-Arbutin via a scalable and cost-effective biological route.
Our Arbutin engineering service is dedicated to pursuing the following production goals:
High Stereo-Selectivity Icon
Enzymatic synthesis guarantees the exclusive production of the desired alpha-Arbutin isomer, avoiding racemic mixtures .
Sustainable and Scalable Production Icon
Microbial fermentation eliminates reliance on low-yielding plant extraction and supports large-scale industrial output.
High Titer and Cost Reduction Icon
Precursor boosting and efficient glycosylation lead to high titer, significantly reducing production costs. [Image of Cost Reduction Icon]
Reduced By-product Formation Icon
Targeted enzymatic pathways minimize the formation of unwanted side products and impurities.
Simplified Purification Icon
High purity output from the enzymatic step simplifies downstream processing compared to chemical synthesis mixtures.
We provide a reliable, high-purity, and cost-effective source for alpha-Arbutin.
Our Arbutin engineering service offers two main research workflows: Bioconversion (Enzymatic) or Whole-Cell Synthesis (Metabolic):
Technical communication is maintained throughout the process, focusing on timely feedback regarding yield and product quality attributes.
Explore the potential for a high-titer, high-purity alpha-Arbutin supply. CD Biosynsis provides customized strain and process engineering solutions:
What is the difference between alpha-Arbutin and beta-Arbutin ?
Both are hydroquinone glucosides, but they differ in the stereoconfiguration of the glycosidic bond. alpha-Arbutin has an alpha-glycosidic bond, while beta-Arbutin has a beta-glycosidic bond. alpha-Arbutin is generally preferred in cosmetics because it shows higher tyrosinase inhibition and greater stability .
Why is enzymatic bioconversion preferred over chemical synthesis?
Chemical synthesis is non-selective and produces a mix of alpha- and beta-Arbutin (racemic mixture in some steps or anomers in glycosylation). Enzymatic bioconversion using alpha-Glucosidase is stereo-selective , guaranteeing a high-purity stream of the alpha-Arbutin isomer.
How do you enhance hydroquinone precursor production?
We metabolically engineer E. coli or yeast by overexpressing the rate-limiting enzymes in the Shikimate pathway (e.g., AroG and TktA) to increase carbon flux. We then introduce enzymes like 4-hydroxyphenylacetate 3-hydroxylase to convert precursors to hydroquinone.
What is UGT and its role in whole-cell synthesis?
UGT is Uridine-diphospho-glycosyltransferase. In whole-cell synthesis, UGT is the enzyme responsible for transferring a sugar molecule (glucose) from an activated sugar donor (UDP-glucose) to hydroquinone, forming the final Arbutin product with high specificity.
What is the estimated project timeline?
A project focusing on enzymatic bioconversion with enzyme engineering typically requires 18-24 weeks . A full whole-cell synthesis project from glucose requires 28-36 weeks for final strain delivery and validation.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.